Abstracts tagged "interleukins (IL) and therapeutic targeting"

Abstract Number: 1167 • 2015 ACR/ARHP Annual Meeting
Treating Experimental Arthritis with Adenoviral Overexpression of IL-22 or with Blocking Antibodies Against Endogenous IL-22 Both Reduces Inflammation and Destruction
Marije I. Koenders¹, Debbie M. Roeleveld¹, Loreto Parga¹, Shahla Abdolahi-Roodsaz¹, Fons A.J. van de Loo¹, Jay K. Kolls² and Peter M. van der Kraan¹, ¹Experimental Rheumatology, Radboud university medical center, Nijmegen, Netherlands, ²Richard King Mellon Foundation Institute for Pediatric Research, Children's Hospital of Pittsburgh of UPMC, Pittsburgh, PA
Background/Purpose: Interleukin-22 (IL-22) is an IL-10 family cytokine member that was recently discovered to be mainly produced by Th17 cells. Previous studies have indicated the…
Abstract Number: 1036 • 2014 ACR/ARHP Annual Meeting
Synergism Between GM-CSF and IL-17 Causes Enhanced Joint Pathology Via the Production of IL-6 and IL-23
Annemarie E.M. van Nieuwenhuijze¹, Debbie M. Roeleveld², Birgitte Walgreen², Miranda Bennink¹, Monique M. Helsen¹, Liduine van den Bersselaar¹, Ian P. Wicks³, Wim B. van den Berg¹, Fons A. van de Loo¹ and Marije I. Koenders¹, ¹Experimental Rheumatology, Radboud university medical center, Nijmegen, Netherlands, ²Experimentel Rheumatology, Radboud university medical center, Nijmegen, Netherlands, ³Inflammation, The Walter and Eliza Hall Institute of Medical Research, Melbourne, Australia
Background/Purpose: T helper-17 (Th17) cells are important mediators of inflammatory diseases, and are the main pathogenic cell type in many animal models of autoimmunity. Recent…

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].